A new drug for the treatment of head and neck cancer has been accepted for use on the NHS.
Nivolumab, marketed as Opdivo, was one of four medicines approved by the Scottish Medicines Consortium (SMC).
The drug, used to treat cancer of the head and neck, including of the mouth and throat, can improve overall survival and help patients maintain quality of life during their remaining months.
Its approval was welcomed by Cancer Research UK, which said Nivolumab would offer another treatment to those whose disease has progressed on or after chemotherapy.
Gregor McNie of the charity said: "Head and neck cancer is very difficult to treat once it has relapsed or spread, and options, including surgery and radiotherapy, are limited.
"So it is fantastic news that Nivolumab will be made available for some patients in Scotland with this devastating disease."
The SMC has also approved the use of Stiripentol (Diacomit) for the treatment of children with a very rare type of epilepsy known as Dravet's syndrome.
This type of epilepsy appears in young children, and can cause prolonged and repeated seizures.
Stiripentol, which was accepted for use in combination with two other medicines, may significantly reduce the frequency of seizures.
Baricitinib (Olumiant) was accepted for the treatment of severe rheumatoid arthritis in adults who have not responded to or are intolerant of other current treatments, while rolapitant (Varuby) was accepted for the prevention of delayed nausea and vomiting associated with cancer chemotherapy in adults.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here